Infection duration and inflammatory imbalance are associated with atherosclerotic risk in HIV-infected never-smokers independent of antiretroviral therapy

AIDS

Volumn 27, Issue 16, 2013, Pages 2603-2614

  Desvarieux, Moïse ^a,b   Boccara, Franck ^b,c,e   Meynard, Jean Luc ^b,c   Bastard, Jean Phillipe ^c,d,e   Mallat, Ziad ^f,h   Charbit, Beny ^g   Demmer, Ryan T ^a   Haddour, Nabila ^b,c   Fellahi, Soraya ^b,d,e   Tedgui, Alain ^f   Cohen, Ariel ^b,c   Capeau, Jacqueline ^c,d,e   Boyd, Anders ⁱ   Girard, Pierre Marie ^b,c,i  

^a Mailman School of Public Health ^*  (United States)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL TENON   (France)

^e CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^f PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ INSERM   (France)

Author keywords

antiretroviral; carotid intima media thickness; HIV; infection duration; inflammatory imbalance; smoking

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CYTOKINE; D DIMER; INSULIN; INTEGRASE INHIBITOR; INTERLEUKIN 18; INTERLEUKIN 27; INTERLEUKIN 6; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RESISTIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERUM AMYLOID A;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; SCORING SYSTEM; SMOKING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; RISK FACTORS; TIME FACTORS;

EID: 84885405993     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283634819     Document Type: Article

References (47)

1. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-1608.
2. Jerico C, Knobel H, Calvo N, Sorli ML, Guelar A, Gimeno-Bayon JL, et al. Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. Stroke 2006; 37:812-817.
3. Thiebaut R, Aurillac-Lavignolle V, Bonnet F, Ibrahim N, Cipriano C, Neau D, et al. Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitaine Cohort, 1999-2004. AIDS 2005; 19:729-731.
4. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
5. Lang S, Mary-Krause M, Simon A, Partisani M, Gilquin J, Cotte L, et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis 2012; 55:600-607.
6. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
7. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148: 728-736.
8. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Relationship between inflammatory markers, endothe-lial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119-1127.
9. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-241.
10. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010; 7:4-10.
11. Vaiopoulos AG, Marinou K, Christodoulides C, Koutsilieris M. The role of adiponectin in human vascular physiology. Int J Cardiol 2011; 155:188-193.
12. United States Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Questionnaire. Atlanta, Georgia: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2006.
13. Institut de recherche et documentation en économie de la santé. Enquête sur la Santé et la Protection Sociale. Paris, France: Institut de recherche et documentation en économie de la santé; 2004.
14. Santé Québec. Enquête Sociale et de Santé. Montréal, Canada: Health Canada; 1998.
15. Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR Jr, Sacco RL, et al. Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation 2005; 111:576-582.
16. Feise RJ. Do multiple outcome measures require P-value adjustment?. BMC Med Res Methodol 2002; 2:8.
17. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
18. Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(M). HIV Med 2011; 12:412-421.
19. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702-710.
20. Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19:927-933.
21. Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. Cardiovascular disease in HIV infection. Am Heart J 2006; 151:1147-1155.
22. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol 2013; 61:511-523.
23. van Vonderen MG, Hassink EA, van Agtmael MA, Stehouwer CD, Danner SA, Reiss P, et al. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis 2009; 199:1186-1194.
24. Ho JE, Deeks SG, Hecht FM, Xie Y, Schnell A, Martin JN, et al. Initiation of antiretroviral therapy at higher nadir CD4R T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2010; 24:1897-1905.
25. Medina S, Wessman D, Krause D, Stepenosky J, Boswell G, Crum-Cianflone N. Coronary aging in HIV-infected patients. Clin Infect Dis 2010; 51:990-993.
26. van Vonderen MG, Smulders YM, Stehouwer CD, Danner SA, Gundy CM, Vos F, et al. Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr 2009; 50:153-161.
27. Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis 2011; 214:468-473.
28. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059-1067.
29. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
30. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
31. Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, et al. Changes in inflammatory and coagulation biomar-kers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011; 56:36-43.
32. Escote X, Miranda M, Veloso S, Domingo P, Alonso-Villaverde C, Peraire J, et al. Lipodystrophy and insulin resistance in combination antiretroviral treated HIV-1-infected patients: implication of resistin. J Acquir Immune Defic Syndr 2011; 57:16-23.
33. Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ, et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 2006; 3:e287.
34. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev 2010; 21:331-344.
35. Yoshida H, Miyazaki Y. Interleukin 27 signaling pathways in regulation of immune and autoimmune responses. Int J Bio-chem Cell Biol 2008; 40:2379-2383.
36. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23:929-939.
37. Guzzo C, Hopman WM, Che Mat NF, Wobeser W, Gee K. Impact of HIV infection, highly active antiretroviral therapy, and hepatitis C coinfection on serum interleukin-27. AIDS 2010; 24:1371-1374.
38. Bezante GP, Briatore L, Rollando D, Maggi D, Setti M, Ghio M, et al. Hypoadiponectinemia in lipodystrophic HIV individuals: a metabolic marker of subclinical cardiac damage. Nutr Metab Cardiovasc Dis 2009; 19:277-282.
39. Samaras K, Gan SK, Peake PW, Carr A, Campbell LV. Proin-flammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. Obesity (Silver Spring) 2009; 17:53-59.
40. Calvert PA, Liew TV, Gorenne I, Clarke M, Costopoulos C, Obaid DR, et al. Leukocyte telomere length is associated with high-risk plaques on virtual histology intravascular ultrasound and increased proinflammatory activity. Arterioscler Thromb Vasc Biol 2011; 31:2157-2164.
41. Freitas WM, Quaglia LA, Santos SN, Soares AA, Japiassu AV, Boaventura V, et al. Association of systemic inflammatory activity with coronary and carotid atherosclerosis in the very elderly. Atherosclerosis 2011; 216:212-216.
42. Sikka G, Miller KL, Steppan J, Pandey D, Jung SM, Fraser CD 3rd, et al. Interleukin 10 knockout frail mice develop cardiac and vascular dysfunction with increased age. Exp Gerontol 2013; 48:128-135.
43. Kostense S, Vandenberghe K, Joling J, Van Baarle D, Nanlohy N, Manting E, et al. Persistent numbers of tetramerR CD8(R) T cells, but loss of interferon-gammaR HIV-specific T cells during progression to AIDS. Blood 2002; 99:2505-2511.
44. Ingram JT, Yi JS, Zajac AJ. Exhausted CD8 T cells downregulate the IL-18 receptor and become unresponsive to inflammatory cytokines and bacterial co-infections. PLoS Pathog 2011; 7:e1002273.
45. Mackerness KJ, Cox MA, Lilly LM, Weaver CT, Harrington LE, Zajac AJ. Pronounced virus-dependent activation drives exhaustion but sustains IFN-gamma transcript levels. J Immunol 2010; 185:3643-3651.
46. Zureik M, Touboul PJ, Bonithon-Kopp C, Courbon D, Berr C, Leroux C, et al. Cross-sectional and 4-year longitudinal associations between brachial pulse pressure and common carotid intima-media thickness in a general population. The EVA study. Stroke 1999; 30:550-555.
47. Ando F, Takekuma K, Niino N, Shimokata H. Ultrasonic evaluation of common carotid intima-media thickness (IMT): influence of local plaque on the relationship between IMT and age. J Epidemiol 2000; 10:S10-17.